These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16686314)

  • 1. Bone cytokines and renal osteodystrophy in peritoneal dialysis patients.
    Mesquita M; Wittersheim E; Demulder A; Dratwa M; Bergmann P
    Adv Perit Dial; 2005; 21():181-4. PubMed ID: 16686314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients.
    Grzegorzewska AE; Mlot M
    Adv Perit Dial; 2005; 21():188-93. PubMed ID: 16686316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum markers of bone turnover in dialyzed patients grouped by level of intact parathyroid hormone.
    Grzegorzewska AE; Mlot-Michalska M
    Adv Perit Dial; 2006; 22():203-6. PubMed ID: 16983970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased levels of osteoprotegerin in hemodialysis patients.
    Avbersek-Luznik I; Malesic I; Rus I; Marc J
    Clin Chem Lab Med; 2002 Oct; 40(10):1019-23. PubMed ID: 12476941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease.
    Grzegorzewska AE; Młot M
    Rocz Akad Med Bialymst; 2004; 49():190-2. PubMed ID: 15631341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis.
    Wittersheim E; Mesquita M; Demulder A; Guns M; Louis O; Melot C; Dratwa M; Bergmann P
    Clin Biochem; 2006 Jun; 39(6):617-22. PubMed ID: 16530745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism.
    Mazziotti G; Amato G; Sorvillo F; Piscopo M; Rizzo MR; Lalli E; Iride L; Cioffi M; Molinari AM; Paolisso G; Carella C
    Eur J Endocrinol; 2006 Mar; 154(3):373-7. PubMed ID: 16498049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.
    Gonnelli S; Montagnani A; Caffarelli C; Cadirni A; Campagna MS; Franci MB; Lucani B; Gaggiotti E; Nuti R
    J Endocrinol Invest; 2005 Jun; 28(6):534-9. PubMed ID: 16117195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease.
    Hegedus D; Ferencz V; Lakatos PL; Meszaros S; Lakatos P; Horvath C; Szalay F
    J Bone Miner Res; 2002 Nov; 17(11):1961-7. PubMed ID: 12412803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis.
    Granchi D; Pellacani A; Spina M; Cenni E; Savarino LM; Baldini N; Giunti A
    J Bone Joint Surg Am; 2006 Jul; 88(7):1501-9. PubMed ID: 16818976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
    Morabito N; Gaudio A; Lasco A; Atteritano M; Pizzoleo MA; Cincotta M; La Rosa M; Guarino R; Meo A; Frisina N
    J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
    Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
    J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet.
    Fiore CE; Pennisi P; Ferro G; Ximenes B; Privitelli L; Mangiafico RA; Santoro F; Parisi N; Lombardo T
    Horm Metab Res; 2006 Jun; 38(6):417-22. PubMed ID: 16823725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
    Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.